Novellia
PrivateLast Round
Series A
Jun 2, 2026
Total Funding Raised
$28M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Novellia operates in Healthcare & Life Sciences and is based in New York City, New York. Its latest recorded funding round was a Series A round in June 2026.
Novellia is a healthcare technology company that provides a patient-facing platform for consolidating, managing, and sharing longitudinal medical records while also aggregating anonymized data for medical research.
Sector
Healthcare & Life Sciences
Verticals
Healthcare Analytics, Medical AI, Clinical Trials, Patient Engagement, Precision Medicine
Business Model
B2B
Customer Profile
Data as a Service, Subscription SaaS, Services & Consulting, Freemium, Government Contracts
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Novellia Comparables
Compare Novellia with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Briya | 83% | |
| Medeloop | 81% | |
| OMNY Health | 80% |
For institutional investors. Book with your work email.
Novellia Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jun 2, 2026 | ||||
| Corporate Funding | Aug 7, 2023 |
For institutional investors. Book with your work email.
Novellia Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Fundamental Ventures | Pre Seed |
| Khosla Ventures | Series A, Early Funding |
| Acrew Capital | Series A |
| Spark Capital | Early Funding, Series A |
| Daiichi Sankyo | Corporate Funding |
| TMV | Series A |
| Bling Capital | Series A, Early Funding |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Partnering with SABCS/AACR for data publication and research.
- Jul 25, 2026
Partnering with ASCO for data publication and research.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 26, 2026
Novellia attends the NORD Rare Diseases & Orphan Products Breakthrough Summit in District of Columbia on Oct 26th '26, with its EDS research findings to be presented as Poster #IR026.
- recognized_asSep 24, 2026
Crain's New York Business names Novellia one of its 2026 Best Places to Work in New York City, recognizing its employee-driven culture, in New York on Sep 24th '26.
- receives_awardSep 24, 2026
Novellia is a 2026 MedTech Breakthrough Award winner for Best Healthcare Data Repository Solution.
For institutional investors. Book with your work email.
Novellia Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Novellia's valuation, stock price, and market status.
Is Novellia a public or private company?
Novellia is a private company.
What is the current stock price of Novellia?
Novellia is a private company, so its shares have no public market price. Caplight tracks Novellia's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Novellia worth (valuation)?
Valuation information for Novellia is not publicly available.
Can I buy Novellia stock?
Novellia shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Novellia's last funding round?
Novellia's most recent funding round was Series A on June 2, 2026.
Who are the main investors in Novellia?
Key investors in Novellia include Spark Capital.
Will Novellia IPO soon?
No public IPO plans have been announced for Novellia.
How can I track Novellia secondary market activity?
Caplight tracks bids, offers, and trades in Novellia's shares on secondary markets.